Abstract
The resistance to selective EGFR inhibitors involves the activation of alternative signaling pathways, and Akt activation and VEGF induction have been described in EGFR inhibitor-resistant tumors. Combined inhibition of EGFR and other signaling proteins has become a successful therapeutic approach, stimulating the search for further determinants of resistance as basis for novel therapeutic strategies. We established human cancer cell lines with various degrees of EGFR expression and sensitivity to EGFR inhibitors and analyzed signal transducers under the control of EGFR-dependent and EGFR-independent pathways. Multitargeted inhibitor vandetanib (ZD6474) inhibited the growth and the phosphorylation of Akt and its effector p70S6 kinase in both wild-type and EGFR inhibitor-resistant human colon, prostate, and breast cancer cells. We found that the resistant cell lines exhibit, as common feature, VEGFR-1/Flt-1 overexpression, increased secretion of VEGF and placental growth factor, and augmented migration capabilities and that vandetanib is able to antagonize them. Accordingly, a new kinase assay revealed that in addition to VEGF receptor (VEGFR)-2, RET, and EGFR, vandetanib efficiently inhibits also VEGFR-1. The contribution of VEGFR-1 to the resistant phenotype was further supported by the demonstration that VEGFR-1 silencing in resistant cells restored sensitivity to anti-EGFR drugs and impaired migration capabilities, whereas exogenous VEGFR-1 overexpression in wild-type cells conferred resistance to these agents. This study shows that VEGFR-1 contributes to anti-EGFR drug resistance in different human cancer cells. Moreover, vandetanib inhibits VEGFR-1 activation, cell proliferation, and migration, suggesting its potential utility in patients resistant to EGFR inhibitors.
Highlights
Purpose:The resistance to selective epidermal growth factor receptor (EGFR) inhibitors involves the activation of alternative signaling pathways, and Akt activation and Vascular endothelial growth factor (VEGF) induction have been described in EGFR inhibitor ^ resistant tumors
We provide mechanistic evidence of the correlation betweenVEGFR-1activity and EGFR drug resistance.These data imply that detection ofVEGFR-1on tumor cells may indicate their increased ability to survive and invade and to escape the inhibition by EGFR inhibitors used in clinical practice, such as cetuximab and gefitinib
Human cancer cell lines resistant to EGFR inhibitors are sensitive to vandetanib
Summary
Purpose:The resistance to selective EGFR inhibitors involves the activation of alternative signaling pathways, and Akt activation and VEGF induction have been described in EGFR inhibitor ^ resistant tumors. Using a panel of tumor cells of different types and with different degrees of sensitivity or resistance to epidermal growth factor receptor (EGFR) inhibitors, we show that resistant tumors share the following common features : vascular endothelial growth factor receptor (VEGFR)-1/Flt-1 overexpression and Akt activation, increased secretion of VEGF and placental growth factor, and augmented migration capabilities. We provide mechanistic evidence of the correlation betweenVEGFR-1activity and EGFR drug resistance.These data imply that detection ofVEGFR-1on tumor cells may indicate their increased ability to survive and invade and to escape the inhibition by EGFR inhibitors used in clinical practice, such as cetuximab and gefitinib Another finding concerns the small-molecule vandetanib/ZD6474, whose mechanisms of action have been documented by us in several previous studies. Inhibition of VEGFR-1 in primary tumors prevents endothelial cell migration by interfering with the chemotactic response and by diminishing vascular investment with perivascular cells [22]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
